I think the potential of Agenic is to rethink how work gets done overall. It challenges all sorts

of traditional orthodoxies around how organizations execute the work at hand. That's Jason Gersatus,

CEO of Deloitte U.S., talking about the transformational potential of Agenic AI. Join him later

to learn why agents are a game changer for businesses across industries.

Here's your morning T&B Tech Minute for Monday, June 22nd. I'm Danny Lewis for the Wall Street

Journal. We exclusively report that biotech company Regen XBio says the U.S. Food and Drug

Administration has agreed to reverse its rejection of an

experimental gene therapy. The therapy targets Hunter Syndrome, a rare, fatal, genetic disease

that causes irreversible brain damage and cell death. The About Face is the latest by the agency

that's under new leadership and marks a broader retreat from demands that rare disease drug makers

test their experimental medicines against placebos to make sure the drugs work.

After filing an appeal, RegenXBio says the FDA indicated it would drop demands for the new study.

The FDA did not respond to a request for comment.

Chevron has struck a 20-year agreement to sell electricity to Microsoft to power what could

become one of the country's largest AI data centers. The oil company is working with energy company

Juulant to supply the West Texas data center with natural gas produced in the area. The companies

didn't disclose a cost estimate for the project. The data center will have its own on-site power plant instead of being plugged into the

Texas grid, but will connect to the grid at a later date to sell excess electricity into

the power market.

The deal cements Chevron's lead in the race among major oil companies to bank on the data center

boom.

And a Chinese robotics company, backed by SoftBank Group, is gearing up to

...